APA (7th ed.) Citation

Di Raimondo, F., Kyriakou, C., Schmidt-Hieber, M., Vekemans, M., Payer, A. R., Bentsen, P. T., . . . Plesner, T. (2017). European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM). Clinical Lymphoma Myeloma and Leukemia, 17(1), e62. https://doi.org/10.1016/j.clml.2017.03.113

Chicago Style (17th ed.) Citation

Di Raimondo, Francesco, et al. "European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM)." Clinical Lymphoma Myeloma and Leukemia 17, no. 1 (2017): e62. https://doi.org/10.1016/j.clml.2017.03.113.

MLA (8th ed.) Citation

Di Raimondo, Francesco, et al. "European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM)." Clinical Lymphoma Myeloma and Leukemia, vol. 17, no. 1, 2017, p. e62, https://doi.org/10.1016/j.clml.2017.03.113.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.